Scrip
Face-to-Face: Allon targets tau pathology with lead drug davunetide
25 January 2010
Nancy Faigen
Please Login to read the full article.
25 January 2010
Nancy Faigen
nancy.faigen@informausa.com
As
Allon Therapeutics prepares to advance its lead drug candidate, davunetide intranasal (formerly AL-108), into proof-of-concept trials for progressive supranuclear palsy (PSP), its chief medical officer,
Dr Steven Whitaker told
Scrip of the company's excitement at its potential as a treatment...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
- Face-to-Face: Trophos - The French firm that hooked Actelion
- Face-to-Face: Trophos looks to nourish ALS market with olesoxime
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
